- Home
- BRTX vs HBIO Comparison
BRTX vs HBIO Comparison
Compare BRTX & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- HBIO
- Stock Information
- Founded
- BRTX 1997
- HBIO 1901
- Country
- BRTX United States
- HBIO United States
- Employees
- BRTX 11
- HBIO N/A
- Industry
- BRTX Managed Health Care
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- BRTX Health Care
- HBIO Industrials
- Exchange
- BRTX Nasdaq
- HBIO Nasdaq
- Market Cap
- BRTX 13.7M
- HBIO 13.0M
- IPO Year
- BRTX N/A
- HBIO 2000
- Fundamental
- Price
- BRTX $1.67
- HBIO $0.36
- Analyst Decision
- BRTX Strong Buy
- HBIO Buy
- Analyst Count
- BRTX 1
- HBIO 2
- Target Price
- BRTX $18.00
- HBIO $3.00
- AVG Volume (30 Days)
- BRTX 27.4K
- HBIO 1.1M
- Earning Date
- BRTX 05-14-2025
- HBIO 05-12-2025
- Dividend Yield
- BRTX N/A
- HBIO N/A
- EPS Growth
- BRTX N/A
- HBIO N/A
- EPS
- BRTX N/A
- HBIO N/A
- Revenue
- BRTX $401,000.00
- HBIO $91,397,000.00
- Revenue This Year
- BRTX $446.88
- HBIO N/A
- Revenue Next Year
- BRTX $39.53
- HBIO $8.58
- P/E Ratio
- BRTX N/A
- HBIO N/A
- Revenue Growth
- BRTX 175.03
- HBIO N/A
- 52 Week Low
- BRTX $1.03
- HBIO $0.33
- 52 Week High
- BRTX $2.55
- HBIO $4.08
- Technical
- Relative Strength Index (RSI)
- BRTX 41.86
- HBIO 43.83
- Support Level
- BRTX $1.66
- HBIO $0.34
- Resistance Level
- BRTX $1.88
- HBIO $0.39
- Average True Range (ATR)
- BRTX 0.08
- HBIO 0.06
- MACD
- BRTX -0.01
- HBIO 0.02
- Stochastic Oscillator
- BRTX 8.33
- HBIO 21.03
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.